Page last updated: 2024-09-05

sorafenib and etoposide

sorafenib has been researched along with etoposide in 14 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(etoposide)
Trials
(etoposide)
Recent Studies (post-2010) (etoposide)
6,5207305,25118,3063,6934,900

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)etoposide (IC50)
nuclear receptor coactivator 1 isoform 1 [Homo sapiens]Homo sapiens (human)1.153
nuclear receptor coactivator 3 isoform aHomo sapiens (human)1.4284
Polyunsaturated fatty acid lipoxygenase ALOX15Oryctolagus cuniculus (rabbit)3.187
Caspase-3Homo sapiens (human)1
DNA topoisomerase 2-betaHomo sapiens (human)0.4299
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)4.18

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (7.14)29.6817
2010's12 (85.71)24.3611
2020's1 (7.14)2.80

Authors

AuthorsStudies
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Xu, Z; Zhang, L1
Liu, Y; Xu, Z; Zhao, SJ1
Deng, X; Jiang, W; Li, Y; Liu, L; Luo, T; Wang, Z; Xie, L; Zhang, X1
Pappo, A; Paulino, AC1
Bernard, S; Chiu, M; Davies, JM; Dees, EC; Dhruva, NS; Hayes, DN; Hilbun, LR; Ivanova, A; Keller, K; Kim, WY; Socinski, MA; Stinchcombe, TE; Walko, CM1
Cawkwell, L; Little, SJ; Maraveyas, A; Murray, A; Stanley, P1
Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W1
Dowlati, A; Fu, P; Halmos, B; Ma, P; Mekhail, T; Nickolich, M; Pennell, N; Sharma, N1
Cheong, J; Jung, HU; Kim, HY; Park, BS; Yoo, KS; Yoo, SH; Yoo, YH; Yun, I1
An, L; Chen, Y; Feng, F; Gao, X; Lu, Y; Qu, J; Sun, H; Wang, C; Wang, F; Yang, Y; Zeng, Z; Zhang, C1
Cao, Y; Feng, F; Hou, MX; Jia, H; Jiang, QY; Ma, HD; Sun, HW; Wang, T; Yang, Q; Yang, YP1
Gerber, JM; Grunwald, MR; Induru, R; McDonnell, MH1

Reviews

4 review(s) available for sorafenib and etoposide

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Coumarin-containing hybrids and their anticancer activities.
    European journal of medicinal chemistry, 2019, Nov-01, Volume: 181

    Topics: Animals; Antineoplastic Agents; Coumarins; Drug Design; Drug Discovery; Humans; Neoplasms; Structure-Activity Relationship

2019
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
    European journal of medicinal chemistry, 2019, Dec-01, Volume: 183

    Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles

2019
Cutaneous manifestations in leukemia patients.
    Seminars in oncology, 2016, Volume: 43, Issue:3

    Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Dermatomycoses; Etoposide; Humans; Leukemia; Mastocytosis; Niacinamide; Paraneoplastic Syndromes; Phenylurea Compounds; Skin Diseases, Bacterial; Skin Neoplasms; Sorafenib

2016

Trials

2 trial(s) available for sorafenib and etoposide

ArticleYear
A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
    Lung cancer (Amsterdam, Netherlands), 2011, Volume: 71, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Pemetrexed; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2011
Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer.
    Investigational new drugs, 2014, Volume: 32, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Small Cell Lung Carcinoma; Sorafenib; Treatment Outcome

2014

Other Studies

8 other study(ies) available for sorafenib and etoposide

ArticleYear
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
Design, synthesis and biological evaluation of 3-arylisoquinoline derivatives as topoisomerase I and II dual inhibitors for the therapy of liver cancer.
    European journal of medicinal chemistry, 2022, Jul-05, Volume: 237

    Topics: Alkaloids; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Design; Humans; Isoquinolines; Liver Neoplasms; Molecular Docking Simulation; Phosphatidylinositol 3-Kinases; Structure-Activity Relationship; Topoisomerase II Inhibitors

2022
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
    Pediatric blood & cancer, 2009, Dec-15, Volume: 53, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Child; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dactinomycin; Etoposide; Fatal Outcome; Female; Foot; Groin; Humans; Ifosfamide; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Lymphatic System; Male; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Rhabdomyosarcoma, Alveolar; Salvage Therapy; Soft Tissue Neoplasms; Sorafenib; Temozolomide; Thigh; Vincristine

2009
Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.
    Oncology reports, 2010, Volume: 24, Issue:4

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Administration Schedule; Endothelial Cells; Etoposide; Humans; In Vitro Techniques; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide

2010
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
    Cancer biology & therapy, 2011, Aug-01, Volume: 12, Issue:3

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Camptothecin; Carcinoma, Hepatocellular; Cell Death; Cell Nucleus; Cytoplasm; Deoxycytidine; Doxorubicin; Drug Synergism; Etoposide; Female; Fluorouracil; Gemcitabine; Genes, p53; Humans; Irinotecan; Liver Neoplasms; Mice; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Quinacrine; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2011
Sorafenib overcomes the chemoresistance in HBx-expressing hepatocellular carcinoma cells through down-regulation of HBx protein stability and suppresses HBV gene expression.
    Cancer letters, 2014, Dec-01, Volume: 355, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cisplatin; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Viral; Hep G2 Cells; Hepatitis B virus; Humans; Interferon-alpha; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Protein Stability; Sorafenib; Trans-Activators; Transfection; Viral Regulatory and Accessory Proteins

2014
MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
    Current cancer drug targets, 2015, Volume: 15, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Etoposide; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Molecular Targeted Therapy; Niacinamide; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Sorafenib

2015
Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
    Biochimica et biophysica acta, 2016, Volume: 1860, Issue:7

    Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; Male; Mice, SCID; MicroRNAs; Niacinamide; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Quercetin; Receptor, Notch1; Signal Transduction; Sorafenib; Transfection; Xenograft Model Antitumor Assays

2016